New nicotinic analogue ZY-1 enhances cognitive functions in a transgenic mice model of Alzheimer's disease

Neuroscience Letters

Volumn 537, Issue , 2013, Pages 29-34

  Nie, Huizhen ^a,b   Wang, Zejian ^a   Zhao, Wenjuan ^a   Lu, Jinmiao ^a   Zhang, Can ^a   Lok, Kenghoe ^a   Wang, Yuliang ^a   Shen, Hanlin ^a   Xu, Zheng ^c   Yin, Ming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b School of Medicine   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

4 2 nAChR; Alzheimer's disease; Morris water maze; Tg APPswe PS1dE9 transgenic mice

Indexed keywords

HUPERZINE A; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BRAIN; COGNITION; CONTROLLED STUDY; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ALKALOIDS; ALZHEIMER DISEASE; ANIMALS; CELL LINE; ESCAPE REACTION; MAZE LEARNING; MICE; MICE, TRANSGENIC; NICOTINE; NICOTINIC AGONISTS; RADIOLIGAND ASSAY; REACTION TIME; RECEPTORS, NICOTINIC; SESQUITERPENES;

EID: 84874372314     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.01.001     Document Type: Article

References (29)

1. Cincotta S.L., Yorek M.S., Moschak T.M., Lewis S.R., Rodefer J.S. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curr. Opin. Investig. Drugs 2008, 9(1):47-56.
2. French K.L., Granholm A.C., Moore A.B., Nelson M.E., Bimonte-Nelson H.A. Chronic nicotine improves working and reference memory performance and reduces hippocampal NGF in aged female rats. Behav. Brain Res. 2006, 169:256-262.
3. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006, 24:516-524.
4. Giacobini E. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 2000, Suppl. 1:S3-S10.
5. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
6. Hellström-Lindahl E. Modulation of β-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur. J. Pharmacol. 2000, 393:255-263.
7. Hurst R., Rollema H., Bertrand D. Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol. Ther. 2012, August [Epub ahead of print].
8. Koffie R.M., Meyer-Luehmann M., Hashimoto T. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4012-4017.
9. Lloyd G.K., Williams M. Neural nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. 2000, 292:461-467.
10. Martin-Ruiz C.M., Court J.A., Molnar E., Lee M., Gotti C., Mamalaki A., Tsouloufis T., Tzartos S., Ballard C., Perry R.H., Perry E.K. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J. Neurochem. 1999, 73:1635-1640.
11. Masters C.L., Simms G., Weinman N.A. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1985, 82(12):4245-4249.
12. McCallum S.E., Collins A.C., Paylor R., Marks M.J. Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation. Psychopharmacology 2006, 184:314-327.
13. Moriguchi S. Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II. Pharmacol. Sci. 2011, 117(1):6-11.
14. Morris R.G.M. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
15. Mousavi M., Hellström-Lindahl E. Nicotinic receptor agonists and antagonists increase sAPPa secretion and decrease Aβ levels in vitro. Neurochem. Int. 2009, 54:237-244.
16. Mura E., Zappettini S., Preda S., Biundo F., Lanni C., Grilli M., Cavallero A., Olivero G., Salamone A., Govoni S., Marchi M. Dual effect of beta-amyloid on (7 and (4(2 nicotinic receptors controlling the release of glutamate, aspartate and GABA in rat hippocampus. PLoS ONE 2012, 7(1):e29661. [Epub 2012, January].
17. Nie H., Li Z., Lukas R.J. Construction of SH-EP1-alpha4beta2-hAPP695 cell line and effects of nicotinic agonists on beta-amyloid in the cells. Cell. Mol. Neurobiol. 2008, 28(1):103-112.
18. Nie H.Z., Shi S., Lukas R.J. Activation of α7 nicotinic receptor affects APP processing by regulating secretase activity in SH-EP1-α7 nAChR-hAPP695 cells. Brain Res. 2010, 1356:112-120.
19. Onoue S., Yamamoto N., Seto Y., Yamada S. Pharmacokinetic study of nicotine and its metabolites cotinine to clarify possible association between smoking and voiding dysfunction in rats using UPLC/ESI-MS. Drug Metab. Pharmacokinet. 2011, 26(4):416-422.
20. Pákáski M., Kálmán J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem. Int. 2008, 53:103-111.
21. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 2000, 61:75-111.
22. Picciotto M.R., Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front. Biosci. 2008, 13:492-504.
23. Sabey K., Paradiso K., Zhang J., Steinbach J.H. Ligand binding and activation of rat nicotinic α4β2 receptors stably expressed in HEK293 cells. Mol. Pharmacol. 1999, 55:58-66.
24. Selkoe D.J. The origins of Alzheimer disease: a is for amyloid. JAMA 2000, 283(12):1615-1617.
25. Taly A., Corringer P.J., Guedin D., Lestage P., Changeux J.P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov. 2009, 8(9):733-750.
26. Taniuchi N., Niidome T., Goto Y., Akaike A., T.Kihara. Decreased proliferation of hippocampal progenitor cells in APPswe/PS1dE9 transgenic mice. Neuroreport 2007, 18:1801-1805.
27. Wevers A., Schroder H. Nicotinic acetylcholine receptors in Alzheimer's disease. J. Alzheimer's Dis. 1999, 1:207-219.
28. Zhang J., Liu Q., Chen Q. Nicotine attenuates β-amyloid-induced neurotoxicity by regulating metal homeostasis. FASEB J. 2006, 20(8):1212-1214.
29. Zhang L.J., Xiao Y., Qi X.L. Cholinesterase activity and mRNA level of nicotinic acetylcholine receptors (alpha4 and beta2 Subunits) in blood of elderly Chinese diagnosed as Alzheimer's disease. J. Alzheimer's Dis. 2010, 19(3):849-858.